Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Predictors and Clinical Outcomes of Vasoplegia in Patients Bridged to Heart Transplantation With Continuous‐Flow Left Ventricular Assist Devices
Alnsasra, Hilmi , Daly, Richard C. , Schettle, Sarah , Briasoulis, Αlexandros , Taher, Riad, Stulak, John M., Behfar, Atta , Pereira, Naveen L. , Frantz, Robert P. , Edwards, Brooks S., Clavell, Alfredo L. , Kushwaha, Sudhir S. , Asleh, Rabea , Schettle, Sarah D., Dunlay, Shannon M. , Behfar, Atta , Briasoulis, Alexandros , Frantz, Robert P

Mayo Clinic

Journal of the American Heart Association | November 8, 2019 | Volume: 8 | Issue: 22 | Pages: No page available

10.1161/jaha.119.013108 | PMID 31701791 Get It

Background The presence of a durable left ventricular assist device ( LVAD ) is associated with increased risk of vasoplegia in the early postoperative period following heart transplantation ( HT ). However, preoperative predictors of vasoplegia and its impact on survival after HT are unknown. We sought to examine predictors and outcomes of patients who develop vasoplegia after HT following bridging therapy with an LVAD . Methods and Results We identified 94 patients who underwent HT after bridging with continuous‐flow LVAD from 2008 to 2018 at a single institution. Vasoplegia was defined as persistent low vascular resistance requiring ≥2 intravenous vasopressors within 48 hours after HT for >24 hours to maintain mean arterial pressure >70 mm Hg. Overall, 44 patients (46.8%) developed vasoplegia after HT . Patients with and without vasoplegia had similar preoperative LVAD , echocardiographic, and hemodynamic parameters. Patients with vasoplegia were significantly older; had longer LVAD support, higher preoperative creatinine, longer cardiopulmonary bypass time, and higher Charlson comorbidity index; and more often underwent combined organ transplantation. In a multivariate logistic regression model, older age (odds ratio: 1.08 per year; P =0.010), longer LVAD support (odds ratio: 1.06 per month; P =0.007), higher creatinine (odds ratio: 3.9 per 1 mg/dL; P =0.039), and longer cardiopulmonary bypass time (odds ratio: 1.83 per hour; P =0.044) were independent predictors of vasoplegia. After mean follow‐up of 4.0 years after HT , vasoplegia was associated with increased risk of all‐cause mortality (hazard ratio: 5.20; 95% CI, 1.71–19.28; P =0.003). Conclusions Older age, longer LVAD support, impaired renal function, and prolonged intraoperative CPB time are independent predictors of vasoplegia in patients undergoing HT after LVAD bridging. Vasoplegia is associated with worse prognosis; therefore, detailed assessment of these predictors can be clinically important.
Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Abu‐Rustum, Nadeem R. , Yashar, Catheryn M. , Bean, Sarah , Bradley, Kristin , Campos, Susana M. , Chon, Hye Sook, Damast, Shari , Dorigo, Oliver , Eifel, Patricia J. , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Han, Ernest , Huh, Warner K. , Lurain, John R., Mariani, Andrea , Nagel, Christa , Nekhlyudov, Larissa , Fader, Amanda N. , Remmenga, Steven W., Reynolds, R. Kevin, Sisodia, Rachel, Tillmanns, Todd , Ueda, Stefanie , Wyse, Emily , McMillian, Nicole R., Scavone, Jillian L., Chu, Christina , Cohn, David E. , Crispens, Marta Ann , Mutch, David G.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 7, 2019 | Volume: 17 | Issue: 11 | Pages: 1374-1391

10.6004/jnccn.2019.0053 | PMID 31693991 Get It

Gestational trophoblastic neoplasia (GTN), a subset of gestational trophoblastic disease (GTD), occurs when tumors develop in the cells that would normally form the placenta during pregnancy. The NCCN Guidelines for Gestational Trophoblastic Neoplasia provides treatment recommendations for various types of GTD including hydatidiform mole, persistent post-molar GTN, low-risk GTN, high-risk GTN, and intermediate trophoblastic tumor.
An Injectable Neural Stimulation Electrode Made from an In‐Body Curing Polymer/Metal Composite
Trevathan, James K. , Baumgart, Ian W. , Nicolai, Evan N. , Gosink, Brian A., Asp, Anders J., Settell, Megan L. , Polaconda, Shyam , Malerick, Kevin D., Brodnick, Sarah K. , Zeng, Weifeng , McConico, Andrea L., Sanger, Zachary , Lee, Jannifer H. , Aho, Johnathon M. , Ross, Erika K., Lujan, Jose L., Williams, Justin C. , Franke, Manfred , Ludwig, Kip A. , Shoffstall, Andrew J. , Knudsen, Bruce E. , Trevathan, James K , Ludwig, Kip A , Shoffstall, Andrew J , Asp, Anders J., Suminski, Aaron J. , Ross, Erika K., Weber, Douglas J.

Mayo Clinic

Advanced Healthcare Materials | November 7, 2019 | Volume: 8 | Issue: 23 | Pages: No page available

10.1002/adhm.201900892 | PMID 31697052 Get It

Abstract Implanted neural stimulation and recording devices hold vast potential to treat a variety of neurological conditions, but the invasiveness, complexity, and cost of the implantation procedure greatly reduce access to an otherwise promising therapeutic approach. To address this need, a novel electrode that begins as an uncured, flowable prepolymer that can be injected around a neuroanatomical target to minimize surgical manipulation is developed. Referred to as the Injectrode, the electrode conforms to target structures forming an electrically conductive interface which is orders of magnitude less stiff than conventional neuromodulation electrodes. To validate the Injectrode, detailed electrochemical and microscopy characterization of its material properties is performed and the feasibility of using it to stimulate the nervous system electrically in rats and swine is validated. The silicone‐metal‐particle composite performs very similarly to pure wire of the same metal (silver) in all measures, including exhibiting a favorable cathodic charge storage capacity (CSC C ) and charge injection limits compared to the clinical LivaNova stimulation electrode and silver wire electrodes. By virtue of its simplicity, the Injectrode has the potential to be less invasive, more robust, and more cost‐effective than traditional electrode designs, which could increase the adoption of neuromodulation therapies for existing and new indications.
Involution of Breast Lobules, Mammographic Breast Density and Prognosis Among Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer Patients
Nyante, Sarah J. , Pfeiffer, Ruth M. , Cora, Renata , Butcher, Donna , Sternberg, Lawrence, Bowles, Erin J. Aiello , Fan, Shaoqi , Figueroa, Jonine D. , Weinmann, Sheila , Hoover, Robert N. , Brinton, Louise A. , González, Amy Berrington de , Glass, Andrew G., Sherman, Mark E. , Gierach, Gretchen L. , Pfeiffer, Ruth M , Cora, Renata , Fan, Shaoqi , Gierach, Gretchen L , Figueroa, Jonine D , Nyante, Sarah , Berrington de Gonzalez, Amy , Mullooly, Maeve

Mayo Clinic

Journal of Clinical Medicine | November 4, 2019 | Volume: 8 | Issue: 11 | Pages: 1868

10.3390/jcm8111868 | PMID 31689948 Get It

Mammographic breast density (MD) reflects breast fibroglandular content. Its decline following adjuvant tamoxifen treated, estrogen receptor (ER)-positive breast cancer has been associated with improved outcomes. Breast cancers arise from structures termed lobules, and lower MD is associated with increased age-related lobule involution. We assessed whether pre-treatment involution influenced associations between MD decline and risk of breast cancer-specific death. ER-positive tamoxifen treated patients diagnosed at Kaiser Permanente Northwest (1990–2008) were defined as cases who died of breast cancer (n = 54) and matched controls (remained alive over similar follow-up; n = 180). Lobule involution was assessed by examining terminal duct lobular units (TDLUs) in benign tissues surrounding cancers as TDLU count/mm2, median span and acini count/TDLU. MD (%) was measured in the unaffected breast at baseline (median 6-months before) and follow-up (median 12-months after tamoxifen initiation). TDLU measures and baseline MD were positively associated among controls (p < 0.05). In multivariable regression models, MD decline (≥10%) was associated with reduced risk of breast cancer-specific death before (odds ratio (OR): 0.41, 95% CI: 0.18–0.92) and after (OR: 0.41, 95% CI: 0.18–0.94) adjustment for TDLU count/mm2, TDLU span (OR: 0.34, 95% CI: 0.14–0.84), and acini count/TDLU (OR: 0.33, 95% CI: 0.13–0.81). MD decline following adjuvant tamoxifen is associated with reduced risk of breast cancer-specific death, irrespective of pre-treatment lobule involution.
Comparative Treatment Outcomes for Patients With Idiopathic Subglottic Stenosis
Gelbard, Alexander , Anderson, Catherine , Berry, Lynne D. , Amin, Milan R. , Benninger, Michael S. , Blumin, Joel H. , Bryson, Paul C. , Castellanos, Paul F., Chen, Sheau‐Chiann , Cohen, Seth M. , Crawley, Brianna K. , Dailey, Seth H. , Daniero, James J. , Alarcón, Alessandro de , Donovan, Donald T., Edell, Eric S. , Ekbom, Dale C. , Fernandes‐Taylor, Sara , Fink, Daniel S. , Franco, Ramon A. , Garrett, C. Gaelyn , Guardiani, Elizabeth , Hoffman, Henry T. , Hogikyan, Norman D. , Howell, Rebecca J. , Huang, Li‐Ching , Hussain, Lena K., Johns, Michael M. , Kasperbauer, Jan L. , Khosla, Sid , Kinnard, Cheryl, Kupfer, Robbi A. , Langerman, Alexander , Lentz, Robert J. , Lorenz, Robert R. , Lowery, Anne S. , Makani, Samir, Maldonado, Fabien , Mannion, Kyle , Matrka, Laura , McWhorter, Andrew J., Meratı, Albert L., Mori, Matthew , Netterville, James L. , O’Dell, Karla , Ongkasuwan, Julina , Postma, Gregory N. , Reder, Lindsay , Rohde, Sarah L. , Richardson, Brent E. , Rickman, Otis B. , Rosen, Clark A. , Rutter, Michael J. , Sandhu, Guri, Schindler, Joshua S. , Schneider, Glenn Todd , Shah, Rupali N., Sikora, Andrew G. , Sinard, Robert J. , Smith, Marshall E. , Smith, Libby J. , Soliman, Ahmed M. S. , Sveinsdóttir, Sigríður, Daele, Douglas J. Van , Veivers, David , Verma, Sunil P., Weissbrod, Philip A. , Wootten, Christopher T. , Shyr, Yu , Francis, David O. , Chen, Sheau-Chiann , Ongkasuwan, Julian , Cohen, Seth M , Hoffman, Henry T , Richardson, Brent E , Gelbard, Alexander , Weissbrod, Philip A , Bock, Jonathan M. , Clary, Matthew S. , Hillel, Alexander T. , Lott, David G. , Weinberger, Paul , Amin, Milan R

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | October 31, 2019 | Volume: 146 | Issue: 1 | Pages: 20

10.1001/jamaoto.2019.3022 | PMID 31670805 Get It

Patient Experiences and Outcomes of a Telehealth Clinical Care Pathway for Postoperative Inflammatory Bowel Disease Patients
Nguyen, Audrey , Stokes, Zack , Deen, Welmoed K. van , Platt, Anya, Jacobs, Rutger J. , Reardon, Sarah, Kane, Ellen, Sack, Jonathan, Hommes, Daniël W. , Lightner, Amy, Zand, Aria , Lightner, Amy L.

Mayo Clinic

Telemedicine and e-Health | October 31, 2019 | Volume: 26 | Issue: 7 | Pages: 889-897

10.1089/tmj.2019.0102 | PMID 31670610 Get It

National trends in coronary intensive care unit admissions, resource utilization, and outcomes
Woolridge, Sarah, Alemayehu, Wendimagegn , Kaul, Padma , Lawler, Patrick R. , Lemay, Michel, Wong, Graham C., Lawler, Patrick , Fordyce, Christopher B. , Lemay, Michel, Jentzer, Jacob C. , Goldfarb, Michael , Armstrong, Paul W. , Diepen, Sean van

Mayo Clinic

European Heart Journal. Acute Cardiovascular Care | October 30, 2019 | Volume: 9 | Issue: 8 | Pages: 923-930

10.1177/2048872619883400 | PMID 31663772 Get It

Background: Emerging evidence suggests that coronary intensive care units are evolving into intensive care environments with an increasing burden of non-cardiovascular illness, but previous studies have been limited to older populations or single center experiences. Methods: Canadian national health-care data was used to identify all patients ≥18 years admitted to dedicated coronary intensive care units (2005–2015) and admissions were categorized as primary cardiac or non-cardiac. The outcomes of interest included longitudinal trends in admission diagnoses, critical care therapies, and all-cause in-hospital mortality. Results: Among the 373,992 patients admitted to a coronary intensive care unit, minimal changes in the proportion of patients admitted with a primary cardiac (88.2% to 86.9%; p&lt;0.001) and non-cardiac diagnoses (11.8% to 13.1%; p&lt;0.001) were observed. Among cardiac admissions, a temporal increase in the proportion of ST-segment elevation myocardial infarction (19.4% to 24.1%, p&lt;0.001), non-ST-segment elevation myocardial infarction (14.6% to 16.2%, p&lt;0.001), heart failure (7.3% to 8.4%, p&lt;0.001), shock (4.9% to 5.7%, p&lt;0.001), and decline in unstable angina (4.9% to 4.0%, p&lt;0.001) and stable coronary diseases (21.3% to 12.4%, p&lt;0.001) was observed. The proportion of patients requiring critical care therapies (57.8% to 63.5%, p&lt;0.001) including mechanical ventilation (9.6% to 13.1%, p&lt;0.001) increased. In-hospital mortality rates for patients with primary cardiac (4.9% to 4.4%; adjusted odds ratio 0.71, 95% confidence interval 0.63–0.79) and non-cardiac (17.8% to 16.1%; adjusted odds ratio 0.84, 0.73–0.97) declined; results were consistent when stratified by academic vs community hospital, and by the presence of on-site percutaneous coronary intervention. Conclusion: In a national dataset we observed a changing case-mix among patients admitted to a coronary intensive care unit, though the proportion of patients with a primary cardiac diagnosis remained stable. There was an increase in clinical acuity highlighted by critical care therapies, but in-hospital mortality rates for both primary cardiac and non-cardiac conditions declined across all hospitals. Our findings confirm the changing coronary intensive care unit case-mix and have implications for future coronary intensive care unit training and staffing.
Gender Differences in Self-perception of Health at a Wellness Center
Sood, Richa , Jenkins, Sarah M. , Sood, Amit , Clark, Matthew M.

Mayo Clinic

American Journal of Health Behavior | October 30, 2019 | Volume: 43 | Issue: 6 | Pages: 1129-1135

10.5993/ajhb.43.6.10 | PMID 31662171 Get It

Objective: Understanding gender differences in self-perception of health (SPH) and self-efficacy can inform the design of tailored programs to improve health behaviors. We aimed to assess gender-specific differences in SPH and self-efficacy for maintaining wellness habits at a work-place wellness center. Methods: A workplace wellness center member survey was conducted in 2016. Information about SPH and self-efficacy to maintain wellness habits was assessed. Data were analyzed to assess gender differences in SPH and self-efficacy. Results: The survey was completed by 2784 members (mean age, 49.2 years; 68.2% women). SPH was similar between genders despite more men reporting health problems such as hypertension, diabetes, high cholesterol, and cigarette smoking. Women had higher self-efficacy about maintaining healthy diet, but the difference was not clinically meaningful. Women had lower self-efficacy in their ability to maintain physical activity. Conclusions: In this large cohort of worksite wellness center members, men and women had similar self-perception of health despite higher disease burden among men. Women had lower self-efficacy in their ability to maintain physical activity level but similar self-efficacy for maintaining healthy diet. These differences may inform the design of tailored wellness programs to meet the needs of both genders.
Dissociating the effects of oxygen pressure and content on the control of breathing and acute hypoxic response
Dominelli, Paolo B. , Baker, Sarah E. , Wiggins, Chad C. , Stewart, Glenn M. , Sajgalik, Pavol , Shepherd, John R. A. , Roberts, Shelly K., Roy, Tuhin K. , Curry, Timothy B. , Hoyer, James D., Oliveira, Jennifer L. , Herrick, Jennifer L. , Foster, Glen E , Wiggins, Chad C , Roy, Tuhin K , Baker, Sarah E , Foster, Glen E. , Joyner, Michael J.

Mayo Clinic

Journal of Applied Physiology | October 24, 2019 | Volume: 127 | Issue: 6 | Pages: 1622-1631

10.1152/japplphysiol.00569.2019 | PMID 31647724 Get It

Arterial oxygen tension and oxyhemoglobin saturation ([Formula: see text]) decrease in parallel during hypoxia. Distinguishing between changes in oxygen tension and oxygen content as the relevant physiological stimulus for cardiorespiratory alterations remains challenging. To overcome this, we recruited nine individuals with hemoglobinopathy manifesting as high-affinity hemoglobin [HAH; partial pressure at 50% [Formula: see text] (P50) = 16 ± 0.4 mmHg] causing greater [Formula: see text] at a given oxygen partial pressure compared with control subjects ( n = 12, P50 = 26 ± 0.4 mmHg). We assessed ventilatory and cardiovascular responses to acute isocapnic hypoxia, iso-oxic hypercapnia, and 20 min of isocapnic hypoxia (arterial Po2 = 50 mmHg). Blood gas alterations were achieved with dynamic end-tidal forcing. When expressed as a function of the logarithm of oxygen partial pressure, ventilatory sensitivity to hypoxia was not different between groups. However, there was a significant difference when expressed as a function of [Formula: see text]. Conversely, the rise in heart rate was blunted in HAH subjects when expressed as a function of partial pressure but similar when expressed as a function of [Formula: see text]. Ventilatory sensitivity to hypercapnia was not different between groups. During sustained isocapnic hypoxia, the rise in minute ventilation was similar between groups; however, heart rate was significantly greater in the controls during 3 to 9 min of exposure. Our results support the notion that oxygen tension, not content, alters cellular Po2in the chemosensors and drives the hypoxic ventilatory response. Our study suggests that in addition to oxygen partial pressure, oxygen content may also influence the heart rate response to hypoxia.NEW & NOTEWORTHY We dissociated the effects of oxygen content and pressure of cardiorespiratory regulation studying individuals with high-affinity hemoglobin (HAH). During hypoxia, the ventilatory response, expressed as a function of oxygen tension, was similar between HAH variants and controls; however, the rise in heart rate was blunted in the variants. Our work supports the notion that the hypoxic ventilatory response is regulated by oxygen tension, whereas cardiovascular regulation may be influenced by arterial oxygen content and tension.
LB5. A Long-Time Coming: Final 2-year Analysis of Efficacy, Durability, and Microbiome Changes in a Controlled Open-Label Trial of Investigational Microbiota-Based Drug RBX2660 for Recurrent Clostridioides difficile Infections
Orenstein, Robert , Mische, Sarah, Bancke, Lindy, Su, Xin , Walsh, Dana M. , Harvey, Adam, Gerding, Dale N. , Blount, Ken , Gonzalez, Carlos

Mayo Clinic

Open Forum Infectious Diseases | October 23, 2019 | Volume: 6 | Issue: Supplement_2 | Pages: S994-S995

10.1093/ofid/ofz415.2488 Get It

Abstract Background Recurrent Clostridioides difficile infection (rCDI) is an urgent public health threat associated with significant mortality and medical cost. Microbiota therapy is gaining acceptance as a strategy to reduce rCDI recurrence. We present the final 24-month analysis of clinical safety, efficacy, and microbiome restoration from a Phase 2 open-label trial of RBX2660 for prevention of CDI recurrence. Methods Participants with multi-recurrent CDI received <2 doses of RBX2660 delivered via enema 7 days apart in this multicenter, open-label Phase 2 study. Efficacy was defined as the absence of CDI recurrence through 56 days after the last dose and was compared with 8-week recurrence-free rates for a historical control cohort that received standard-of-care antibiotic therapy. Fisher exact test compared the proportion of treatment participants who were CDI-free by age and sex. Durability was defined as continued absence of CDI episodes beyond 8 weeks. Safety and durability assessments occurred at 3, 6, 12, and 24 months. Participant stool samples were collected prior to and for up to 720 days after treatment, and microbiome changes were assessed by shallow shotgun sequencing. Results The efficacy of RBX2660 to prevent rCDI at 8 weeks (78.9%; 112/142) was higher than the CDI-free rate in the historical control group (30.7%, 23/75; P < 0.0001). Age and sex did not impact efficacy. Among participants who achieved treatment success at 8 weeks and were evaluable for long-term durability (n = 95), 8 experienced a new CDI episode by the 24-month follow-up for an overall durability of 91.6%. The safety profile was consistent with previous reports for RBX2660. In total, 503 stool samples from 110 treatment responders were analyzed. Within 7 days of treatment, the relative abundance of Bacteroidia and Clostridia remained shifted higher than pre-treatment levels while Gammaproteobacteria and Bacilli declined sharply after treatment, and these changes persisted to at least 24 months. Conclusion RBX2660, a microbiota-based drug, was safe and efficacious for preventing rCDI with clinical durability to 24 months after treatment, independent of age or sex, and RBX2660 durability associated with durable microbiome shifts from pre-treatment to a healthier composition. Disclosures Robert Orenstein, DO, Rebiotix Inc. (Advisor or Review Panel member), Sarah Mische, PhD, Rebiotix Inc. (Employee), Ken Blount, PhD, Rebiotix Inc. (Employee), Lindy Bancke, PharmD, Rebiotix Inc. (Employee), Xin Su, MD, MSci, Rebiotix Inc. (Employee), Dana Walsh, PhD, Rebiotix Inc. (Employee), Adam Harvey, PhD, Rebiotix Inc. (Employee), Carlos Gonzalez, MS, Rebiotix Inc. (Consultant), Dale N. Gerding, MD, Rebiotix Inc. (Board Member).